The global market for Pharmaceutical Outsourcing Services (CXO) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Lonza Pharmaceuticals
Thermo Fisher
Caterent
Jubilant LifeSciences
Boehringer Ingelheim
Oxford BioMedica
Charles River
WuXi AppTec
He Yuan Biology
GenScript Biotech
Kanglong Chemical
Porton shares
Notai Biotech
Jiuzhou Pharmaceutical
Kai Laiying
Medici
CXO is a pharmaceutical contract outsourcing service, which mainly includes pharmaceutical contract research and development services (CRO) and pharmaceutical contract production services (CDMOCMO). In the process of new drug R&D, through pharmaceutical contract outsourcing, pharmaceutical companies or biotechnology companies entrust drug R&D and production companies to provide professional R&D services, including the development of technical processes required for the production of drugs, the production of APIs and intermediates, and preparation production.
North American market for Pharmaceutical Outsourcing Services (CXO) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Pharmaceutical Outsourcing Services (CXO) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Pharmaceutical Outsourcing Services (CXO) in Clinical Stage Projects is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Pharmaceutical Outsourcing Services (CXO) include Lonza Pharmaceuticals, Thermo Fisher, Caterent, Jubilant LifeSciences, Boehringer Ingelheim, Oxford BioMedica, Charles River, IQVIA, Labcorp Drug Development, WuXi AppTec, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pharmaceutical Outsourcing Services (CXO), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical Outsourcing Services (CXO).
The Pharmaceutical Outsourcing Services (CXO) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pharmaceutical Outsourcing Services (CXO) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmaceutical Outsourcing Services (CXO) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Lonza Pharmaceuticals
Thermo Fisher
Caterent
Jubilant LifeSciences
Boehringer Ingelheim
Oxford BioMedica
Charles River
IQVIA
Labcorp Drug Development
WuXi AppTec
He Yuan Biology
GenScript Biotech
Kanglong Chemical
Porton shares
Notai Biotech
Jiuzhou Pharmaceutical
Asymchem Laboratories (Tianjin) Co., Ltd.
Shanghai Medicilon Inc.
ChemPartner
AmbioPharm
CordenPharma
Segment by Type
CRO
CMO/CDMO
CSO
Segment by Application
Clinical Stage Projects
Commercialization Stage Projects
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmaceutical Outsourcing Services (CXO) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 CRO
1.2.3 CMO/CDMO
1.2.4 CSO
1.3 麻豆原创 by Application
1.3.1 Global Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Clinical Stage Projects
1.3.3 Commercialization Stage Projects
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Perspective (2020-2031)
2.2 Global Pharmaceutical Outsourcing Services (CXO) Growth Trends by Region
2.2.1 Global Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Pharmaceutical Outsourcing Services (CXO) Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Pharmaceutical Outsourcing Services (CXO) Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Dynamics
2.3.1 Pharmaceutical Outsourcing Services (CXO) Industry Trends
2.3.2 Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Drivers
2.3.3 Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Challenges
2.3.4 Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical Outsourcing Services (CXO) Players by Revenue
3.1.1 Global Top Pharmaceutical Outsourcing Services (CXO) Players by Revenue (2020-2025)
3.1.2 Global Pharmaceutical Outsourcing Services (CXO) Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Pharmaceutical Outsourcing Services (CXO) Revenue
3.4 Global Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Concentration Ratio
3.4.1 Global Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical Outsourcing Services (CXO) Revenue in 2024
3.5 Global Key Players of Pharmaceutical Outsourcing Services (CXO) Head office and Area Served
3.6 Global Key Players of Pharmaceutical Outsourcing Services (CXO), Product and Application
3.7 Global Key Players of Pharmaceutical Outsourcing Services (CXO), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical Outsourcing Services (CXO) Breakdown Data by Type
4.1 Global Pharmaceutical Outsourcing Services (CXO) Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Pharmaceutical Outsourcing Services (CXO) Forecasted 麻豆原创 Size by Type (2026-2031)
5 Pharmaceutical Outsourcing Services (CXO) Breakdown Data by Application
5.1 Global Pharmaceutical Outsourcing Services (CXO) Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Pharmaceutical Outsourcing Services (CXO) Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size (2020-2031)
6.2 North America Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size by Country (2020-2025)
6.4 North America Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size (2020-2031)
7.2 Europe Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size by Country (2020-2025)
7.4 Europe Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size (2020-2031)
9.2 Latin America Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Pharmaceutical Outsourcing Services (CXO) 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza Pharmaceuticals
11.1.1 Lonza Pharmaceuticals Company Details
11.1.2 Lonza Pharmaceuticals Business Overview
11.1.3 Lonza Pharmaceuticals Pharmaceutical Outsourcing Services (CXO) Introduction
11.1.4 Lonza Pharmaceuticals Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.1.5 Lonza Pharmaceuticals Recent Development
11.2 Thermo Fisher
11.2.1 Thermo Fisher Company Details
11.2.2 Thermo Fisher Business Overview
11.2.3 Thermo Fisher Pharmaceutical Outsourcing Services (CXO) Introduction
11.2.4 Thermo Fisher Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.2.5 Thermo Fisher Recent Development
11.3 Caterent
11.3.1 Caterent Company Details
11.3.2 Caterent Business Overview
11.3.3 Caterent Pharmaceutical Outsourcing Services (CXO) Introduction
11.3.4 Caterent Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.3.5 Caterent Recent Development
11.4 Jubilant LifeSciences
11.4.1 Jubilant LifeSciences Company Details
11.4.2 Jubilant LifeSciences Business Overview
11.4.3 Jubilant LifeSciences Pharmaceutical Outsourcing Services (CXO) Introduction
11.4.4 Jubilant LifeSciences Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.4.5 Jubilant LifeSciences Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Pharmaceutical Outsourcing Services (CXO) Introduction
11.5.4 Boehringer Ingelheim Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.5.5 Boehringer Ingelheim Recent Development
11.6 Oxford BioMedica
11.6.1 Oxford BioMedica Company Details
11.6.2 Oxford BioMedica Business Overview
11.6.3 Oxford BioMedica Pharmaceutical Outsourcing Services (CXO) Introduction
11.6.4 Oxford BioMedica Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.6.5 Oxford BioMedica Recent Development
11.7 Charles River
11.7.1 Charles River Company Details
11.7.2 Charles River Business Overview
11.7.3 Charles River Pharmaceutical Outsourcing Services (CXO) Introduction
11.7.4 Charles River Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.7.5 Charles River Recent Development
11.8 IQVIA
11.8.1 IQVIA Company Details
11.8.2 IQVIA Business Overview
11.8.3 IQVIA Pharmaceutical Outsourcing Services (CXO) Introduction
11.8.4 IQVIA Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.8.5 IQVIA Recent Development
11.9 Labcorp Drug Development
11.9.1 Labcorp Drug Development Company Details
11.9.2 Labcorp Drug Development Business Overview
11.9.3 Labcorp Drug Development Pharmaceutical Outsourcing Services (CXO) Introduction
11.9.4 Labcorp Drug Development Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.9.5 Labcorp Drug Development Recent Development
11.10 WuXi AppTec
11.10.1 WuXi AppTec Company Details
11.10.2 WuXi AppTec Business Overview
11.10.3 WuXi AppTec Pharmaceutical Outsourcing Services (CXO) Introduction
11.10.4 WuXi AppTec Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.10.5 WuXi AppTec Recent Development
11.11 He Yuan Biology
11.11.1 He Yuan Biology Company Details
11.11.2 He Yuan Biology Business Overview
11.11.3 He Yuan Biology Pharmaceutical Outsourcing Services (CXO) Introduction
11.11.4 He Yuan Biology Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.11.5 He Yuan Biology Recent Development
11.12 GenScript Biotech
11.12.1 GenScript Biotech Company Details
11.12.2 GenScript Biotech Business Overview
11.12.3 GenScript Biotech Pharmaceutical Outsourcing Services (CXO) Introduction
11.12.4 GenScript Biotech Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.12.5 GenScript Biotech Recent Development
11.13 Kanglong Chemical
11.13.1 Kanglong Chemical Company Details
11.13.2 Kanglong Chemical Business Overview
11.13.3 Kanglong Chemical Pharmaceutical Outsourcing Services (CXO) Introduction
11.13.4 Kanglong Chemical Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.13.5 Kanglong Chemical Recent Development
11.14 Porton shares
11.14.1 Porton shares Company Details
11.14.2 Porton shares Business Overview
11.14.3 Porton shares Pharmaceutical Outsourcing Services (CXO) Introduction
11.14.4 Porton shares Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.14.5 Porton shares Recent Development
11.15 Notai Biotech
11.15.1 Notai Biotech Company Details
11.15.2 Notai Biotech Business Overview
11.15.3 Notai Biotech Pharmaceutical Outsourcing Services (CXO) Introduction
11.15.4 Notai Biotech Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.15.5 Notai Biotech Recent Development
11.16 Jiuzhou Pharmaceutical
11.16.1 Jiuzhou Pharmaceutical Company Details
11.16.2 Jiuzhou Pharmaceutical Business Overview
11.16.3 Jiuzhou Pharmaceutical Pharmaceutical Outsourcing Services (CXO) Introduction
11.16.4 Jiuzhou Pharmaceutical Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.16.5 Jiuzhou Pharmaceutical Recent Development
11.17 Asymchem Laboratories (Tianjin) Co., Ltd.
11.17.1 Asymchem Laboratories (Tianjin) Co., Ltd. Company Details
11.17.2 Asymchem Laboratories (Tianjin) Co., Ltd. Business Overview
11.17.3 Asymchem Laboratories (Tianjin) Co., Ltd. Pharmaceutical Outsourcing Services (CXO) Introduction
11.17.4 Asymchem Laboratories (Tianjin) Co., Ltd. Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.17.5 Asymchem Laboratories (Tianjin) Co., Ltd. Recent Development
11.18 Shanghai Medicilon Inc.
11.18.1 Shanghai Medicilon Inc. Company Details
11.18.2 Shanghai Medicilon Inc. Business Overview
11.18.3 Shanghai Medicilon Inc. Pharmaceutical Outsourcing Services (CXO) Introduction
11.18.4 Shanghai Medicilon Inc. Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.18.5 Shanghai Medicilon Inc. Recent Development
11.19 ChemPartner
11.19.1 ChemPartner Company Details
11.19.2 ChemPartner Business Overview
11.19.3 ChemPartner Pharmaceutical Outsourcing Services (CXO) Introduction
11.19.4 ChemPartner Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.19.5 ChemPartner Recent Development
11.20 AmbioPharm
11.20.1 AmbioPharm Company Details
11.20.2 AmbioPharm Business Overview
11.20.3 AmbioPharm Pharmaceutical Outsourcing Services (CXO) Introduction
11.20.4 AmbioPharm Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.20.5 AmbioPharm Recent Development
11.21 CordenPharma
11.21.1 CordenPharma Company Details
11.21.2 CordenPharma Business Overview
11.21.3 CordenPharma Pharmaceutical Outsourcing Services (CXO) Introduction
11.21.4 CordenPharma Revenue in Pharmaceutical Outsourcing Services (CXO) Business (2020-2025)
11.21.5 CordenPharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Lonza Pharmaceuticals
Thermo Fisher
Caterent
Jubilant LifeSciences
Boehringer Ingelheim
Oxford BioMedica
Charles River
IQVIA
Labcorp Drug Development
WuXi AppTec
He Yuan Biology
GenScript Biotech
Kanglong Chemical
Porton shares
Notai Biotech
Jiuzhou Pharmaceutical
Asymchem Laboratories (Tianjin) Co., Ltd.
Shanghai Medicilon Inc.
ChemPartner
AmbioPharm
CordenPharma
听
听
*If Applicable.
